OncoImmunology (Dec 2022)
Trial watch: Dendritic cell (DC)-based immunotherapy for cancer
- Raquel S Laureano,
- Jenny Sprooten,
- Isaure Vanmeerbeerk,
- Daniel M Borras,
- Jannes Govaerts,
- Stefan Naulaerts,
- Zwi N Berneman,
- Benoit Beuselinck,
- Kalijn F Bol,
- Jannie Borst,
- an Coosemans,
- Angeliki Datsi,
- Jitka Fučíková,
- Lisa Kinget,
- Bart Neyns,
- Gerty Schreibelt,
- Evelien Smits,
- Rüdiger V Sorg,
- Radek Spisek,
- Kris Thielemans,
- Sandra Tuyaerts,
- Steven De Vleeschouwer,
- I Jolanda M de Vries,
- Yanling Xiao,
- Abhishek D Garg
Affiliations
- Raquel S Laureano
- Laboratory of Cell Stress & Immunity, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, Belgium
- Jenny Sprooten
- Laboratory of Cell Stress & Immunity, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, Belgium
- Isaure Vanmeerbeerk
- Laboratory of Cell Stress & Immunity, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, Belgium
- Daniel M Borras
- Laboratory of Cell Stress & Immunity, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, Belgium
- Jannes Govaerts
- Laboratory of Cell Stress & Immunity, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, Belgium
- Stefan Naulaerts
- Laboratory of Cell Stress & Immunity, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, Belgium
- Zwi N Berneman
- Department of Haematology, Antwerp University Hospital, Edegem, Belgium
- Benoit Beuselinck
- Department of General Medical Oncology, UZ Leuven, Leuven, Belgium
- Kalijn F Bol
- Department of Tumour Immunology, Radboud Institute for Molecular Life Sciences; Radboud University Medical Center, Nijmegen, The Netherlands
- Jannie Borst
- Department of Immunology and Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands
- an Coosemans
- Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, ImmunOvar Research Group, Ku Leuven, Leuven Cancer Institute, Leuven, Belgium
- Angeliki Datsi
- Institute for Transplantation Diagnostics and Cell Therapeutics, Heinrich-Heine University, Düsseldorf, Germany
- Jitka Fučíková
- Sotio Biotech, Prague, Czech Republic
- Lisa Kinget
- Department of General Medical Oncology, UZ Leuven, Leuven, Belgium
- Bart Neyns
- Department of Medical Oncology, UZ Brussel, Brussels, Belgium
- Gerty Schreibelt
- Department of Tumour Immunology, Radboud Institute for Molecular Life Sciences; Radboud University Medical Center, Nijmegen, The Netherlands
- Evelien Smits
- Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Edegem, Belgium
- Rüdiger V Sorg
- Institute for Transplantation Diagnostics and Cell Therapeutics, Heinrich-Heine University, Düsseldorf, Germany
- Radek Spisek
- Sotio Biotech, Prague, Czech Republic
- Kris Thielemans
- Laboratory of Molecular and Cellular Therapy, Vrije Universiteit Brussel, Brussels, Belgium
- Sandra Tuyaerts
- Department of Medical Oncology, UZ Brussel, Brussels, Belgium
- Steven De Vleeschouwer
- Research Group Experimental Neurosurgery and Neuroanatomy, KU Leuven, Leuven, Belgium
- I Jolanda M de Vries
- Department of Tumour Immunology, Radboud Institute for Molecular Life Sciences; Radboud University Medical Center, Nijmegen, The Netherlands
- Yanling Xiao
- Department of Immunology and Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands
- Abhishek D Garg
- Laboratory of Cell Stress & Immunity, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, Belgium
- DOI
- https://doi.org/10.1080/2162402X.2022.2096363
- Journal volume & issue
-
Vol. 11,
no. 1
Abstract
Dendritic cell (DC)-based vaccination for cancer treatment has seen considerable development over recent decades. However, this field is currently in a state of flux toward niche-applications, owing to recent paradigm-shifts in immuno-oncology mobilized by T cell-targeting immunotherapies. DC vaccines are typically generated using autologous (patient-derived) DCs exposed to tumor-associated or -specific antigens (TAAs or TSAs), in the presence of immunostimulatory molecules to induce DC maturation, followed by reinfusion into patients. Accordingly, DC vaccines can induce TAA/TSA-specific CD8+/CD4+ T cell responses. Yet, DC vaccination still shows suboptimal anti-tumor efficacy in the clinic. Extensive efforts are ongoing to improve the immunogenicity and efficacy of DC vaccines, often by employing combinatorial chemo-immunotherapy regimens. In this Trial Watch, we summarize the recent preclinical and clinical developments in this field and discuss the ongoing trends and future perspectives of DC-based immunotherapy for oncological indications.
Keywords
